SPI Extra
5.916,20
PKT
-25,42
PKT
-0,43
%
Werbung
Analysen zu SPI Extra-Werten
Datum | Rating | Analyst | |
---|---|---|---|
25.07.12 | Swatch (I) buy | Deutsche Bank AG | |
25.07.12 | Swatch (I) outperform | Credit Suisse Group | |
25.07.12 | Clariant hold | ING | |
25.07.12 | Rieter neutral | Sarasin Research | |
25.07.12 | Meyer Burger Technology neutral | Sarasin Research | |
25.07.12 | Lonza neutral | Sarasin Research | |
25.07.12 | Swatch (I) buy | UBS AG | |
25.07.12 | Ascom buy | UBS AG | |
25.07.12 | Meyer Burger Technology hold | Vontobel Research | |
25.07.12 | Rieter hold | Vontobel Research | |
25.07.12 | Lonza hold | Vontobel Research | |
25.07.12 | Comet buy | Vontobel Research | |
24.07.12 | Swatch (I) buy | Sarasin Research | |
24.07.12 | ams-OSRAM buy | Vontobel Research | |
24.07.12 | Julius Bär equal-weight | Morgan Stanley | |
24.07.12 | Baloise reduce | Nomura | |
24.07.12 | ALSO hold | Vontobel Research | |
24.07.12 | Sulzer buy | Vontobel Research | |
24.07.12 | Swatch (I) buy | Vontobel Research | |
23.07.12 | Julius Bär buy | Sarasin Research | |
23.07.12 | Julius Bär buy | ING | |
23.07.12 | Basilea Pharmaceutica hold | Vontobel Research | |
23.07.12 | Arbonia hold | Vontobel Research | |
23.07.12 | Meyer Burger Technology hold | Vontobel Research | |
23.07.12 | Julius Bär hold | Vontobel Research | |
23.07.12 | OC Oerlikon buy | Vontobel Research | |
20.07.12 | Sulzer buy | Sarasin Research | |
20.07.12 | BB Biotech halten | Independent Research GmbH | |
20.07.12 | Mikron hold | Vontobel Research | |
20.07.12 | Sulzer buy | Vontobel Research | |
20.07.12 | Galenica reduce | Vontobel Research | |
20.07.12 | Dätwyler hold | Vontobel Research | |
20.07.12 | Clariant buy | Vontobel Research | |
19.07.12 | Logitech hold | Vontobel Research | |
19.07.12 | Clariant buy | Vontobel Research | |
18.07.12 | Logitech outperform | Exane-BNP Paribas SA | |
19.07.12 | Zug Estates B hold | Vontobel Research | |
18.07.12 | EMS-CHEMIE hold | Vontobel Research | |
18.07.12 | Baloise neutral | Sarasin Research | |
17.07.12 | Barry Callebaut neutral | Sarasin Research |